Biocon informs about disclosure

24 Dec 2024 Evaluate
Biocon has informed that the Company and it European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza® to treat Type-2 Diabetes and Saxenda® used in the treatment of weight management. The above information will also be available on the website of the Company at www.biocon.com. 

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

380.15 2.35 (0.62%)
16-Feb-2026 13:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.25
Dr. Reddys Lab 1269.00
Cipla 1350.00
Zydus Lifesciences 906.85
Lupin 2220.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×